Coronavirus Screening Libraries

Coronaviruses are a large family of viruses that can cause illnesses ranging from the common cold to more serious respiratory infections like bronchitis, pneumonia or severe acute respiratory syndrome (SARS). Rarely, animal coronaviruses can infect people, and even more rarely, these can then spread from person to person through close contact, for example, in a household, workplace or health care centre.

The 2019 novel coronavirus (COVID-19) causes a respiratory infection that originated in Wuhan, China. As of Feb 11, 2020, more than 42,000 cases of 2019-nCoV infection have been confirmed. It has been determined that 2019-nCoV is most closely related to bat SARS-like coronaviruses (exhibiting more than 99% sequence identity), from which SARS-CoV (about 79% identity) evolved, and more distantly related to MERS coronaviruses (about 50% identity).

 

2019-nCoV Main Protease Targeted Library

Deposited in Protein Data Bank in 2020 shortly after the current outbreak of coronavirus disease (COVID-19), the main protease of 2019-nCoV in complex with an inhibitor N3 has been used by Life Chemicals to design the focused library of compounds targeting this crucial virus enzyme. Docking-based virtual screening protocol (Glide by Schrödinger, SP mode) has been employed to search through the Life Chemicals HTS Сollection for potential 2019-nCoV protease active site binders (Fig.1). No docking constraints have been used to allow the docking algorithm to explore as many ligands’ positions and orientations as possible.

More than 2,300 compounds resulting from the screening and filtering by toxicophore/reactive groups comprised the 2019-nCoV library. The library has not been made Ro5 compliant as it would have filtered out many peptide-mimicking compounds.

Dociking of binding mode in the active site of 2019-nCoV main protease.

Figure 1. Binding mode of compound F1259-0053 in the active site of 2019-nCoV main protease. Molecular complex obtained by docking.

eEF1A Targeted Library

According to the recent news related to the COVID-19 potential treatment, it has been proposed that human elongation factor 1-alpha (eEF1A) could be a promising anti-coronavirus drug target. Indeed, a number of publications highlight an important role of eEF1A in virus replication1,2. There is no X-ray data for eEF1A available. However, using the high-quality structural model obtained earlier3, Life Chemicals has designed the eEF1A Targeted Library with docking-based virtual screening. Two distinct binding sites on the surface eEF1A have been used for the docking: GTP-binding site and eEF1B⍺-binding site. No docking constraints have been used since the detailed mechanisms of the binding remain unclear. Results of two separate virtual screens allowed us to select almost 3,000 promising ligands with a high predicted affinity to eEF1A (Fig. 2). These ligands are Ro5-compliant and do not comprise PAINS, toxic or reactive groups. Within this targeted library, separate compound subsets for each binding site are available with docking scores indicated.

Compound F6517-4533 in the eEF1B⍺-binding site of eEF1A, docking model

Figure 2. Binding mode of compound F6517-4533 in the eEF1B⍺-binding site of eEF1A. Molecular complex obtained by docking.

SARS Coronavirus Focused Library

Using 2D fingerprints similarity search approach, a Tanimoto similarity cut-off of 75 % was applied for screening of a reference set of compounds known to be active against SARS coronavirus (data taken from ChEMBL database). The target activities included:

  1. SARS coronavirus
  2. SARS coronavirus 3C-like proteinase
  3. Replicase polyprotein 1ab

All compounds in the reference set were chosen in accordance with accepted maximum activity value (IC50 , KI50 < 1000 nM, Inhibition >25%). In total, almost 300 unique compounds were included into the reference set for subsequent similarity search.

As a result, 437 similar compounds were identified in the Life Chemicals HTS Compound Collection and included in the library.